Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 119,839 | 107,191 | 81,875 | 73,903 | 67,275 |
| Cost of Goods | 60,180 | 49,738 | 42,767 | 42,817 | 42,622 |
| Gross Profit | 59,659 | 57,453 | 39,108 | 31,086 | 24,653 |
| Operating Expenses | 20,201 | 18,990 | 18,054 | 17,670 | 16,590 |
| Operating Income | 39,638 | 39,201 | 21,821 | 14,233 | 8,685 |
| Interest Expense | 3,499 | 3,783 | 3,769 | 6,215 | 6,398 |
| Other Income | 610 | 433 | 349 | -25,662 | 278 |
| Pre-tax Income | 36,749 | 35,851 | 18,401 | -17,644 | 2,565 |
| Income Tax | 840 | 3,789 | 595 | N/A | 0 |
| Net Income Continuous | 35,909 | 32,062 | 17,806 | -17,644 | 2,565 |
| Net Income | $35,909 | $32,062 | $17,806 | $-17,644 | $2,565 |
| EPS Basic Total Ops | 0.15 | 0.14 | 0.08 | -0.08 | 0.01 |
| EPS Basic Continuous Ops | 0.15 | 0.14 | 0.08 | -0.08 | 0.01 |
| EPS Diluted Total Ops | 0.15 | 0.13 | 0.08 | -0.08 | 0.01 |
| EPS Diluted Continuous Ops | 0.15 | 0.13 | 0.08 | -0.08 | 0.01 |
| EPS Diluted Before Non-Recurring Items | 0.15 | 0.13 | 0.08 | N/A | N/A |
| EBITDA(a) | $41,794 | $41,440 | $24,152 | $17,004 | $11,462 |